发明名称 |
EphA2 T-cell epitope agonists and uses therefore |
摘要 |
EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods. |
申请公布号 |
US9359402(B2) |
申请公布日期 |
2016.06.07 |
申请号 |
US201314069208 |
申请日期 |
2013.10.31 |
申请人 |
UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
发明人 |
Storkus Walter J.;Kinch Michael S. |
分类号 |
A61K39/00;C12N15/09;A61K38/00;C07K7/06;C07K14/47;C07K14/705;G01N33/50;G01N33/569;A61K38/17;C07K7/08 |
主分类号 |
A61K39/00 |
代理机构 |
Baker Botts L.L.P. |
代理人 |
Baker Botts L.L.P. |
主权项 |
1. A method of eliciting an immune response to EphA2 in a subject, comprising administering, to the subject, an effective amount of an isolated peptide that consists of 9-35 amino acid residues and wherein said isolated peptide comprises the peptide TLADFDPRV (SEQ ID NO:2, residues 883-891), where said TLADFDPRV (SEQ ID NO:2, residues 883-891) peptide (i) has up to one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D; and (ii) retains the ability to stimulate a T-cell immune response to EphA2 as determined by ELISPOT assay. |
地址 |
Pittsburgh PA US |